# Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without

- 2 extraction of viral RNA
- 4 Mohammad Rubayet Hasan<sup>1,2</sup>, Faheem Mirza<sup>1</sup>, Hamad Al-Hail<sup>1</sup>, Sathyavathi Sundararaju<sup>1</sup>,
- 5 Thabisile Xaba<sup>1</sup>, Muhammad Iqbal<sup>1</sup>, Hashim Alhussain<sup>3</sup>, Hadi Mohamad Yassine<sup>3</sup>, Andres Perez
- 6 Lopez<sup>1,2</sup>, Patrick Tang<sup>1,2</sup>

1

3

7

11

23

- <sup>1</sup>Department of Pathology, Sidra Medicine; <sup>2</sup>Weill Cornell Medical College in Qatar, Doha, Qatar;
- 9 <sup>3</sup>Qatar University, Doha, Qatar
- 10 Short title: SARS-CoV-2 detection by RT-qPCR without RNA extraction
- 12 Corresponding author:
- 13 Mohammad Rubayet Hasan, PhD, FCCM, D(ABMM)
- 14 Clinical Molecular Microbiologist, Department of Pathology
- 15 Assistant Professor of Clinical Pathology and Laboratory Medicine
- Weill Cornell Medical College in Qatar (WCMC-Q)
- 17 Sidra Medicine
- 18 Office no: H2M-24093
- 19 PO Box 26999, Doha, Qatar
- 20 Direct: +974 4003 2996
- 21 Mobile: +974 3003 5501
- 22 mhasan@sidra.org / http://www.sidra.org/doctors/mohammad-rubayet-hasan/

## **Abstract**

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

To circumvent the limited availability of RNA extraction reagents, we aimed to develop a protocol for direct RT-qPCR to detect SARS-CoV-2 in nasopharyngeal swabs without RNA extraction. Nasopharyngeal specimens positive for SARS-CoV-2 and other coronaviruses collected in universal viral transport (UVT) medium were pre-processed by several commercial and laboratory-developed methods and tested by RT-qPCR assays without RNA extraction using different RT-qPCR master mixes. The results were compared to that of standard approach that involves RNA extraction. Incubation of specimens at 65°C for 10 minutes along with the use of TaqPath<sup>TM</sup> 1-Step RT-qPCR Master Mix provides higher analytical sensitivity for detection of SARS-CoV-2 RNA than many other conditions tested. The optimized direct RT-qPCR approach demonstrated a limit of detection of 6.6x10<sup>3</sup> copy/ml and high reproducibility (co-efficient of variation = 1.2%). In 132 nasopharyngeal specimens submitted for SARS-CoV-2 testing, the sensitivity, specificity and accuracy of our optimized approach were 95%, 99% and 98.5%, respectively, with reference to the standard approach. Also, the RT-qPCR C<sub>T</sub> values obtained by the two methods were positively correlated (Pearson correlation coefficient r=0.6971, p=0.0013). The rate of PCR inhibition by the direct approach was 8% compared to 9% by the standard approach. Our simple approach to detect SARS-CoV-2 RNA by direct RT-qPCR may help laboratories continue testing for the virus despite reagent shortages or expand their testing capacity in resource limited settings.

## Introduction

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

The ongoing pandemic of coronavirus disease (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed an unprecedented public health threat to the entire world. In the absence of an effective vaccine or specific treatment against the virus, early detection and contact tracing, physical distancing measures and quarantine of cases are considered the cornerstones to curb the community transmission of SARS-CoV-2 [1-3]. Since the virus was identified and its genome sequenced in early January 2020, detection of viral RNA in respiratory specimens by real-time reverse transcription PCR (RT-qPCR) remains the main approach to manage the outbreak by allowing early detection of cases and targeted measures to prevent transmission of the virus [4]. The massive demand for SARS-CoV-2 RT-qPCR has brought about a global shortage and supply chain irregularities of RNA extraction kits that are crucial for RT-qPCR testing [5-7]. In this study, we tested a number of commercial and laboratory-developed, specimen pre-treatment procedures to optimize the performance of direct RT-qPCR for SARS-CoV-2 avoiding the RNA extraction step. This method was validated against a standard approach that included extraction of viral RNA on a commercial automated extraction platform.

#### Materials and methods

Standard approach for detection of SARS-CoV-2 RNA from nasopharyngeal specimens in our laboratory involves extraction of total nucleic acids from specimens in an IVD-labeled, automated extraction platform followed by RT-qPCR, based on one of the assays (Table 1) suggested by World Health Organization (WHO)[8]. The performance standards of the assay were established in our laboratory according to College of American Pathologists (CAP)

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

standards, and at time of writing this paper, the assay was used to test more than 2000 respiratory specimens to screen patients for potential infection with SARS-CoV-2. Therefore, the assay was used as the reference method for all other alternative approaches assessed in this study. All specimen preparations, pre-treatments and PCR setup were performed in a Class II Biosafety cabinet in a Biosafety level 2 (BSL2) facility. Clinical specimens: Nasopharyngeal flocked swab (NPFS) specimens collected in universal viral transport (UVT) medium (Becton, Dickinson and Company) (n=150) submitted for testing SARS-CoV-2 or other respiratory viruses at Sidra Medicine, Doha, Qatar were used in this study. To maintain patient anonymity, each sample was coded, and all patient identifiers were removed to ensure that personnel involved in this study were unaware of any patient information. Ethics approval was not sought because the study involves laboratory validation of test methods and the secondary use of anonymous pathological specimens that falls under the category 'exempted' by Sidra Medicine Institutional Review Board. For spiking experiments, NPFS specimens (n=6) were collected from laboratory volunteers after obtaining written informed consents. No personal data were collected, and specimens were labeled with random numbers so that test results cannot be linked to an individual. Nucleic acid extraction: Nucleic acids from 0.2 ml of NPFS specimens were extracted on a NucliSENS® easyMAG platform (bioMérieux, France) according to the methods described by the manufacturers. Pre-treatment of specimens: Unless otherwise stated, specimens were diluted using nuclease free water. Heat treatment of specimens at different temperature was performed in a ThermoMixer (Eppendorf). Specimens processed with Arcis Coronavirus RNA extraction research kit (Arcis Biotechnology) were performed according to manufacturer's instructions.

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Briefly, 90 ul specimen was mixed with 6 ul Reagent 1 RTU and either left unheated or heat lysed at 60°C for 5 minutes. 40 µl of lysate was then mixed with 2 µl of Reagent 2a and was used directly for Rt-qPCR. For Takara PrimeDirect™ Probe RT-qPCR Mix (Takara Bio), 0.2 ml specimens were heated at 99°C for 10 mins and then centrifuged at 4000rpm for 5 min. The supernatants were collected and 7µl of supernatant was directly used in RT-qPCR reaction mixture. RT-qPCR: Primers and probes for detection of SARS-CoV-2, HCoV-HKU1 and MS2 bacteriophage are listed in Table S1 [4,9,10]. For detection of HCoV-HKU1 using Quantifast Pathogen RT-PCR + IC kit (Qiagen), five µl of extracted or pre-treated samples were mixed with 20 μl of a master mix containing 5 μl of Quantifast Pathogen RT-PCR + IC Master Mix, 0.25 μl of Quantfast RT Mix and 0.5 µl of 50 x ROX dye solution and primers and probes to final concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 20 min followed by 1 cycle of PCR activation at 95°C for 5 min, followed by 40 amplification cycles each consisting of 95°C-15s and 60°C-60s. For detection of HCoV-HKU1 using TaqPath<sup>TM</sup> 1-Step RT-qPCR kit (Thermofisher Scientific), five µl of extracted or pre-treated samples were mixed with 5 µl of a master mix containing 5 µl of TaqPath<sup>TM</sup> 1-Step RT-qPCR Master Mix and primers and probes to final concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 15 min followed by 1 cycle of polymerase activation at 95°C for 2 min, followed by 40 amplification cycles each consisting of 95°C-15s and 60°C-60s. For detection of SARS-CoV-2 with standard method, five  $\mu l$  of nucleic acid extracts from NucliSENS® easyMAG system were mixed with 7.5 µl of a master mix containing 2.5 µl of

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

Quantifast Pathogen RT-PCR + IC Master Mix, 0.125 µl of Quantfast RT Mix and 0.25 µl of 50 X ROX dye solution and primers and probes to final concentrations shown in Table S1. RNA extraction and PCR inhibition were monitored by an internal control PCR assay, using the primers and probes shown in Table S1. Specimens were spiked with a tittered preparation of MS2 bacteriophage to serve as a template for internal control assay. For direct PCR on specimens, pre-treated specimens were assessed in the same way except that extracted MS2 bacteriophage RNA was mixed with PCR master mix to serve as an inhibition control. A synthetic RNA (IDT) based on E-Sarbeco assay [4] amplicon sequence was used as a positive control. As negative control, 0.2 ml neonatal calf serum (NCS) (Thermofisher Scientific) was extracted along with specimens and used with each PCR run. SARS-CoV-2 RT-qPCR with Takara PrimeDirect<sup>TM</sup> Probe RT-qPCR Mix was performed as described by the manufacturer. Briefly, 7 µl of processed samples were mixed with 18 µl of master mix containing 12.5 µl of PrimeDirect Probe RT-qPCR Mix and primers and probes to final concentrations shown in Table 1. Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with 1 cycle of denaturation at 96°C for 10 sec, 1 cycle of reverse transcription at 60°C for 5 min followed by 45 amplification cycles each consisting of 95°C-5s and 60°C-30s. SARS-CoV-2 RT-qPCR with TaqPath<sup>™</sup> 1-Step RT-qPCR kit with the optimized approach (specimens heat treated at 65°C for 10 min) was performed as above except that 8 µl of specimen was used per 20 μl reaction. A total of 132 NPS that were previously tested by the standard approach were also tested by the optimized, direct approach and the results were compared. In addition, an external quality assessment (EQA) panel (8 specimens) from Quality Control for Molecular Diagnostics (QCMD) was tested simultaneously with the standard and the direct approach, as well as with a

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

QIAstat-Dx Respiratory 2019-nCoV Panel (Qiagen) and the results were compared with expected results. Limit of detection (LOD) study: A SARS-CoV-2 positive nasopharyngeal specimen (C<sub>T</sub> = 23.3) was titered by the optimized approach using synthetic RNA, and serially diluted (up to  $5x10^{-7}$  - fold) using a negative specimen. All diluted specimens were pre-treated by heating at 65°C for 10 min and then assessed by SARS-CoV-2 RT-qPCR in replicates of 8. The C<sub>T</sub> values obtained were used to calculate limit of detection (LOD) and intra-assay reproducibility of direct RT-qPCR. Statistical analysis: Sensitivity, defined as the number of true positive results divided by the sum of true positive and false negative results; specificity, defined as the number of true negative results divided by the sum of true negative and false positive results; and accuracy (concordance), defined as the sum of true positive and true negative results divided by the total number of test samples, were calculated and expressed as percentages. Ninety-five percent confidence intervals (CI) for sensitivity, specificity and accuracy were calculated by the Clopper-Pearson interval or exact method using an online, diagnostic test evaluation calculator (MedCalc, 2018). Correlation between the RT-qPCR CT values between standard approach and optimized direct approach was determined by Pearson's coefficient calculator. The limit of detection with 95% endpoint (C<sub>95</sub>) was determined by Probit regression analysis [11]. **Results** 

Using a human coronavirus HKU1 (hCoV-HKU1) positive specimen as a surrogate for SARS-CoV-2, we first assessed whether specimens can be used directly for RT-qPCR after 2-10 fold dilution with nuclease free water (NFW), simple heat treatment (100°C for 5 min) and

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

centrifugation to remove any insoluble material that may be present in the specimen. The pretreated specimens were then assessed in parallel with extracted specimens by a previously described, laboratory developed RT-qPCR for HCoV-HKU1 (Table S1). A significant loss of sensitivity was observed with a RT-qPCR  $\Delta C_T$  ranging from 10-14 (Table S2). To determine whether any components of UVT medium (Becton, Dickinson and Company) were inhibitory to RT-qPCR, we collected nasopharyngeal flocked swabs (NPFS) from laboratory volunteers in NFW along with swabs in UTM. We then spiked a SARS-CoV-2 positive specimen to all specimens and assessed them by SARS-CoV-2 RT-qPCR. However, no significant improvement in sensitivity was observed (Table S3). Similar results were observed when two commercial test kits were used for direct RTqPCR: Arcis Coronavirus RNA extraction research kit comes with lysis reagents that can be used directly in RT-qPCR; and Takara PrimeDirect<sup>TM</sup> Probe RT-qPCR kit provides a master mix that is compatible with heat-treated specimen extracts. However, in our evaluation both test kits failed to demonstrate an acceptable level of sensitivity (Tables S4 and S5). Our attempts to further optimize the pre-treatment conditions showed modest improvement with a non-ionic detergent, Tween-20, and further improvement with a heating step at 65°C for 10 min without centrifugation ( $\Delta C_T = 5.2$ ) (Table S6). We then tested this low heat approach with more SARS-CoV-2 positive specimens and using 3 different RT-qPCR master mixes. Interestingly, we found that with TaqPath<sup>TM</sup> 1-Step RT-qPCR Master Mix, 4/4 positive samples were correctly detected with a  $\Delta C_T$  range 0.8 – 3.8 (Table 1). On the other hand, two other master mixes gave higher  $\Delta C_T$ and 1/4 positive results were missed by both. Based on these results, the optimal pre-treatment and reaction conditions for the direct approach were: i) transfer and dilute (4-fold) 10 µl of NPFS

specimen in NFW; ii) incubate at 65°C for 10 min; and iii) test 8 μl of heat lysed specimen in a 20 μl reaction using TaqPath<sup>TM</sup> 1-Step RT-qPCR Master Mix.

The analytical sensitivity of the direct RT-qPCR assay using specimens prepared in this manner was determined by serially diluting a specimen positive for SARS-CoV-2 with a negative specimen as a diluent. The positive specimen was titered based on the  $C_T$  value obtained by the direct approach using a standard curve prepared with SARS-CoV-2 synthetic RNA. The  $C_T$  values were linear ( $R^2 = >0.99$ ) over the range of  $10^3$  copy/ml to  $10^8$  copy/ml, the highest concentration used in this analysis (Fig. 1A and 1B). The 95% limit of detection (LOD;  $C_{95}$ ) of the assay with the direct approach was  $6.6X10^3$  copy/ml. The  $C_T$  variation between RT-qPCR replicates across different concentration of analytes were <1 with an average coefficient of variation (CV%) of 1.2%.

A total of 132 NPFS specimens that were previously tested with standard approach including viral RNA extraction were re-tested with the new direct approach. The direct approach detected all except one positive case with  $C_T>38$ . On the other hand, the direct approach detected  $(C_T>37)$  SARS-CoV-2 in one specimen that was negative by standard approach. Overall agreement of results between two approaches was >98% (Kappa= 0.939; 95% CI = 0.854 to 1.000). The sensitivity and specificity of the new approach compared to the reference method were 95% and 99%, respectively (Table 2). The RT-qPCR  $C_T$  values for all specimens that were positive by both methods (n=18) were positively correlated with a Pearson coefficient (R) of 0.6971 (p<0.01) (Fig. 2). The rate of PCR inhibition among the specimens that gave negative RT-qPCR results by the direct approach was 8% compared to 9% by the standard approach. Finally, the direct approach accurately detected SARS-CoV-2 RNA in all except one specimen in an external quality assessment (EQA) panel provided by Quality Control for Molecular

Diagnostics (QCMD)(Table S7). The specimen that gave discrepant result was reported as 'borderline' by QCMD, and SARS-CoV-2 RNA was also undetectable in this specimen by standard approach and by a commercial test, QIAstat-Dx Respiratory 2019-nCoV Panel (Qiagen).

## **Discussion**

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

Success in RT-qPCR testing depends on multiple factors. RNA extraction is preferable to the use of direct specimens because the extraction process concentrates and purifies the RNA targets and excludes PCR inhibitory substances. The use of pre-treated or untreated specimens directly in RT-qPCR is challenging because of the presence of inhibitors and RNA loss due to heating and/or RNases. After many attempts with various pre-treatment agents and conditions, we have determined an optimal pre-treatment protocol complemented with specific RT-qPCR reagents, that generates results equivalent to standard methods that involve RNA extraction. Minimizing RNA loss through the low heat approach, appropriate dilution of inhibitory substances and the higher sensitivity of TaqPath<sup>TM</sup> 1-Step RT-qPCR Master Mix may have played a combinatory role in achieving equivalency of the direct RT-qPCR compared to a standard approach requiring viral RNA extraction. In summary, our new approach demonstrated high sensitivity and specificity in the detection of SARS-CoV-2 RNA, and the rate of RT-qPCR inhibition was similar to that of a standard approach. By skipping the RNA extraction step, the new approach will also significantly reduce the cost and improve the turn-around time of the assay. Delayed and inadequate laboratory testing can significantly hamper efforts to control the pandemic. Our

results will help many labs all over the world who are struggling with a shortage of reagents to

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

continue testing for SARS-CoV-2. Also, because of a significant reduction in cost, the optimized direct approach we described, will be useful to resource-limited countries to expand their capacity for RT-qPCR testing. Acknowledgement We are grateful for the efforts of all technologists in the Molecular Infectious Disease Laboratory at Sidra Medicine. References 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et. Al. A Novel Coronavirus from Patients with Pneumonia in China, N Engl J Med 2019;382(8):727-733. 2. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71-76. Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic, 3. Eurosurveillance. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.14.2000550#r8. Accessed 18 April 2020. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 4. 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25(3). Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators 5. and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med 2020;doi: 10.1056/NEJMp2006141.

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

6. Slabodkin G. FDA chief warns of supply 'pressure' on reagents for coronavirus tests. https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-forcoronavirus-tests/573999/. Accessed 18 April 2020. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-7. CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol 2020;17:e2106. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic. 8. Geneva: WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 18 April 2020. 9. Hasan MR, Al Mana H, Young V, Tang P, Thomas E, Tan R, et al. A novel real-time PCR assay panel for detection of common respiratory pathogens in a convenient, striptube array format. J Virol Methods 2019;265:42-48. Dreier J, Stormer M, Kleesiek K. Use of bacteriophage MS2 as an internal control in viral 10. reverse transcription-PCR assays. J Clin Microbiol 2005;43:4551-7. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. 11. Clin Microbiol Rev 2010;23(3):550-576.

Table 1: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens after heating at 65°C for 10 minutes with different RT-qPCR master mixes

		Sz	ARS-CoV-2 C <sub>T</sub>	
Sample No.	Standard method	Quantifast Pathogen RT- PCR + IC Master Mix	PrimeDirect <sup>TM</sup> Probe RT-qPCR Mix	TaqPath <sup>™</sup> 1-Step RT-qPCR Master Mix
1	21.5	29.4	24.6	22.8
2	34.5	Undetermined	Undetermined	35.3
3	24.5	30.4	28.7	25.5
4	22	29.9	31.4	25.8
5	Undetermined	Undetermined	Undetermined	Undetermined


NPFS specimens were either subjected to viral RNA extraction by standard method using the NucliSENS easyMAG automated extraction system (bioMerieux), or diluted 4-fold with NFW followed by incubation at 65°C for 5 minutes. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using different master mixes in duplicate and mean C<sub>T</sub> values were compared.


Table 2: Performance of optimized direct RT-qPCR approach with reference to standard approach for detection of SARS-CoV-2 RNA

Statistic	Value	95% CI
Total number of specimens	132	-
True positive	18	-
True negative	112	-
False positive	1	-
False negative	1	-
Sensitivity	95.0%	74% to 99.8%
Specificity	99.0%	95.2% to 99.9%
Accuracy	98.5%	94.6% to 99.8%


Figure legends Figure 1: Linearity of SARS-CoV-2 RT-qPCR by direct approach. A tittered SARS-CoV-2 positive nasopharyngeal specimen was serially diluted using a negative specimen, pre-heated at 65°C for 10 min and assessed by SARS-CoV-2 RT-qPCR as described in the Supplemental methods. A) Amplification curves from SARS-CoV-2 RT-qPCR assay on the serially diluted sample. B) RT-qPCR C<sub>T</sub> values were plotted against estimated copy number of SARS-CoV-2 RNA in each dilution. Each data point represents an average of data obtained from 8 replicates. Figure 2: Correlation of RT=qPCR C<sub>T</sub> values obtained by direct versus standard approach.











# **Supplemental Tables**

# Table S1: Primers and probes used in this study

Assay	Target	Name	Sequence (5'- 3')	5'-Label	3'-Label	Final concentratio n (μM)	Source
		HCoV-HKU1-F	GATCCTACTAYTCAAGAAG CTATCCCTACT			0.6	
HCoV- HKU1	Nucleoca psid gene	HCoV-HKU1-R	ACCTTCCTGAGCCTTCAAC ATAAT			0.3	(1)
		HCoV-HKU1-P	TTTYCGCCTGGTACGATTTT GCCTC	JOE/ZEN	IaBkFQ	0.2	
		E_Sarbeco_F1	ACAGGTACGTTAATAGTTA ATAGCGT			0.4	
	E gene	E_Sarbeco_R2	ATATTGCAGCAGTACGCAC ACA			0.4	(2)
SARS-		E_Sarbeco_P1	ACACTAGCCATCCTTACTG CGCTTCG	FAM/ZEN	IaBkFQ	0.2	
CoV-2		MS2-TM3-F	GGCTGCTCGCGGATACCC			0.2	
	Internal control	MS2-TM3-R	TGAGGGAATGTGGGAACC G			0.2	(3)
		MS2-TM2JOE	ACCTCGGGTTTCCGTCTTG CTCGT	JOE/ZEN	IaBkFQ	0.1	

Table S2: Direct RT-qPCR on a nasopharyngeal specimen positive for human coronavirus HKU1 after heat treatment at 100°C for 5 minutes

			HKU1 CoV C <sub>T</sub>		
Sample Name	Sample dilution	Sample processing	Quantifast Pathogen RT-PCR + IC Master Mix	TaqPath <sup>TM</sup> 1-Step RT-qPCR Master Mix	
		easyMAG			
1167-H0	Undiluted	extraction	24.6	23.8	
1167-H1	Undiluted	Heat treatment	36.4	36.6	
1167-H2	2 fold dilution	Heat treatment	34.5	35.7	
1167-Н3	4 fold dilution	Heat treatment	34.7	35.6	
1167-H4	10 fold dilution	Heat treatment	34.1	33.2	
1167-Н5	Undiluted	Freeze thaw; heat treatment	38.1	36.1	

NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS easyMAG automated extraction system (Biomerieux), or ii) serially diluted with nuclease free water (NFW) followed by incubation at 100°C for 5 minutes, or iii) freeze thawed once prior to heat treatment. All heat-treated samples were centrifuged at 13,000 rpm for 5 minutes at 4°C and supernatants were collected. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean  $C_T$  values were compared.

Table S3: Direct RT-qPCR on simulated, dry NPFS using a spiked specimen positive for SARS-CoV-2

Comula No	SARS-CoV-2 C <sub>T</sub>			
Sample No.	Standard method	Direct PCR on dry NPFS		
1	20.8	32.4		
2	20.5	25.8		
3	20.8	32.4		
4	25.7	31.6		
5	25.8	33.8		
6	25.6	34.5		

Specimens were collected from laboratory members who volunteered to provide specimens. NPFS specimens were either i) collected in VTM or ii) collected in sterile empty tubes as dry swabs and later resuspended in 1 ml of NFW. Five  $\mu l$  of a patient specimen positive for SARS-CoV-2 RNA ( $C_T$  = 22) were spiked into 0.2 ml of specimens collected in VTM of NFW. VTM specimens were extracted by standard method using a NucliSENS easyMag automated extraction system (bioMerieux). Specimens collected in NFW were incubated at 100°C for 5 minutes and centrifuged at 13,000 rpm for 5 minutes at 4°C and supernatants were collected. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using Quantifast Pathogen RT-PCR + IC Master Mix in duplicate and mean  $C_T$  values were compared.

Table S4: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using Arcis Pathogen Kit

Sample No.	SARS-CoV-2 $C_T$				
Sample No.	Standard method	Arcis kit with heating	Arcis kit - no heating		
1	Undetermined	Undetermined	Undetermined		
2	Undetermined	Undetermined	Undetermined		
3	Undetermined	Undetermined	Undetermined		
4	25.0	34.9	33.5		
5	21.0	32.9	Undetermined		
6	23.0	28.4	32.3		

NPFS specimens were processed according to manufacturer's protocol (Arcis Biotechnology Ltd.). All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean C<sub>T</sub> values were compared.

Table S5: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using Takara

Sample No	SARS-CoV-2 C <sub>T</sub>			
Sample No.	Standard method	Takara PrimeDirect protocol		
1	21.5	29.78692245		
2	34.5	Undetermined		
3	24.5	Undetermined		
4	33.7	Undetermined		
5	Undetermined	Undetermined		

NPFS specimens were processed according to manufacturer's protocol (PrimeDirect<sup>TM</sup> Probe RT-qPCR Mix, Takara Bio Inc.). All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean  $C_T$  values were compared.

Table S6: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens with or without heating at 65°C for 5 minutes or after lysis using a non-ionic detergent

Sample No.	SARS-CoV-2 C <sub>T</sub>				
	Standard method	No treatment	Heat treatment	Lysis with 0.2% Tween-20	
1	21.5	30.6	26.7	28.4	
2	34.5	Undetermined	Undetermined	Undetermined	
3	Undetermined	Undetermined	Undetermined	Undetermined	
4	Undetermined	Undetermined	Undetermined	Undetermined	
5	Undetermined	Undetermined	Undetermined	Undetermined	

NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS easyMAG automated extraction system (bioMerieux), or ii) diluted 4-fold with nuclease free water (NFW) iii) diluted 4-fold with nuclease free water (NFW) followed by incubation at 65°C for 5 minutes or iv) diluted 4-fold with Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using Quantifast Pathogen RT-PCR + IC Master Mix.

Table S7: Direct RT-qPCR on QCMD EQA specimens

		SARS-CoV-2 C <sub>T</sub>		
Sample No.	QCMD result	Standard approach	QIAstat	Direct approach
Sample 1	Positive	33.4	34	35.5
Sample 2	Negative	undetermined	undetermined	Undetermined
Sample 3	Positive	35.2	35.4	37.1
Sample 4	Negative	undetermined	undetermined	Undetermined
Sample 5	Negative	undetermined	undetermined	Undetermined
Sample 6	Positive	34.2	36.7	35.1
Sample 7	Positive	29.4	31.5	31.7
Sample 8	Borderline	undetermined	undetermined	Undetermined

QCMD EQA specimens were simultaneously tested by standard and direct approach and by QIAstat-Dx Respiratory 2019-nCoV Panel (Qiagen)